Companies To Watch: CalciMedica
By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Long-term planning for pancreatitis, quickly pivoting for COVID pneumonia
CalciMedica has been developing a new class of anti-inflammatory drugs, calcium release-activated calcium (CRAC) channel blockers, with the lead indications for treating acute pancreatitis and viral pneumonia now in Phase 2 trials for its compound, Auxora, an injectable emulsion. Recently, the company discovered the same drug may have a large impact on systemic inflammatory response syndrome (SIRS), the hyperimmunity associated with viral pneumonia, a common comorbidity and comortality condition in COVID-19 disease. Hence, it now has a Phase 3 trial underway with Auxora targeting severe COVID-19 pneumonia.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.